A high dose of IMT504, the PyNTTTTGT prototype immunostimulatory oligonucleotide, does not alter embryonic development in rats

Oligonucleotides

Volumn 20, Issue 1, 2010, Pages 33-35

  Hernando Insúa, Andrés ^a   Rodriguez, Juan M ^a   Elías, Fernanda ^a   Fló, Juan ^a   López, Ricardo ^a   Franco, Raul ^a   Lago, Nestor ^b   Zorzopulos, Jorge ^a   Montaner, Alejandro D ^a,c  

^a Immunotech SA   (Argentina)

^b Gema Biotech   (Argentina)

^c Fundacion Pablo Cassara   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

IMT 504; OLIGODEOXYNUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; GESTATIONAL AGE; HISTOPATHOLOGY; IMMUNOSTIMULATION; MALE; NONHUMAN; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROGENY; RAT; TERATOGENESIS; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC DEVELOPMENT; FEMALE; FLOW CYTOMETRY; OLIGODEOXYRIBONUCLEOTIDES; PREGNANCY; PREGNANCY OUTCOME; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; MUS; RATTUS;

EID: 77649117462     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2009.0206     Document Type: Article

References (17)

1. BARCHET, W., WIMMENAUER, V., SCHLEE, M., and HARTMANN, G. (2008). Accessing the therapeutic potential of immunostimu-latory nucleic acids. Curr. Opin. Immunol. 20, 389-395.
2. CORNISH, K.G., IVERSEN, P., SMITH, L., ARNESON, M., and BAYEVER, E.C. (1993). Cardiovascular effects of a phosphoro-thioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3, 239-247.
3. CORONEL, M.F., HERNANDO-INSÚA, A., RODRIGUEZ, J.M., ELIAS, F., CHASSEING, N.A., MONTANER, A.D., and VILLAR, M.J. (2008) Oligonucleotide IMT504 reduces neuropathic pain after peripheral nerve injury. Neurosci. Lett. 444, 69-73.
4. DORN, A., and KIPPENBERGER, S., (2008). Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immu-nomodulators. Curr. Opin. Mol. Ther. 10, 10-20.
5. ELIAS, F., FLÓ, J., LÓPEZ, R.A., ZORZOPULOS, J., MONTANER, A.D., and RODRIGUEZ, J.M. (2003). Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J. Immunol. 171, 3697-3704.
6. ELIAS, F., FLO, J., RODRIGUEZ, J., DE NICHILO, A., LOPEZ, R.A., ZORZOPULOS, J., NAGLE, C., LAHOZ, M., and MONTANER, A. (2005). PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant Hepatitis B vaccine that enhances the Th1 response. Vaccine. 23, 3597-3603.
7. GALBRAITH, W.M., HOBSON, W.C., GICLAS, P.C., SCHECHTER, P.J., and AGRAWAL, S. (1994). Complement activation and hemo-dynamic changes following intravenous administration of phos-phorohioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201-206.
8. GUPTA, K., and COOPER, C. (2008). A review of the role of CpG oli-godeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R. D. 9, 137-145.
9. HERNANDO INSÚA, A., MONTANER, A.D., RODRIGUEZ, J.M., ELÍAS, F., FLÓ, J., LÓPEZ, R.A., ZORZOPULOS, J., HOFER, E.L., and CHASSEING, N.A. (2007). IMT504, the prototype of the immunostimulatory oligonucleotides of the PyNTTTTGT class, increases the number of progenitors of mesenchymal stem cells both in vitro and in vivo: potential use in tissue repair therapy. Stem Cells. 25, 1047-1054.
10. JURK, M., and VOLLMER, J. (2007). Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs. 21, 387-401.
11. KRIEG, A.M., WU, T., WEERATNA, R., EFLER, S.M., LOVE-HOMAN, L., YANG, L., YI, A.K., SHORT, D., and DAVIS, H.L. (1998). Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA. 12, 631-636.
12. KRUG, A., ROTHENFUSSER, S., HORMUNG, V., JAHRSDORFER, B., BLACKWELL, S., BALLAS, Z.K., ENDRES, S., KRIEG, A.M., and HARTMANN, G. (2001). Identif cation of CpG oligonucle-otide sequences with high induction of IFN-α in plasmacytoid dendritic cells. Eur. J. Immunol. 31, 2154-2163.
13. LANG, P.L., ed. (1993). Historical control data for development and reproductive toxicity studies using the Crl:CD BR rat. Complied by Middle Atlantic Reproduction and Teratology Association. Charles River Laboratories Wilmington, MA.
14. MONTEITH, D.K., HENRY, S.P., HOWARD, R.B., FLOURNOY, S., LEVIN, A.A., BENNETT, C.F., and CROOKE, S.T. (1997). Immune stimulation-a class effect of phosphorothioate oligodeoxynucle-otides in rodents. Anti-Cancer Drug Design. 12, 421-432.
15. MURAD, Y.M., CLAY, T.M., LYERLY, H.K., and MORSE, M.A. (2007). CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert. Opin. Biol. Ther. 7, 1257-1266.
16. PRATER, R.M., JOHNSON, V.J., GERMOLEC, D.R., LUSTER, I.L., and HOLLADAY, S.D. (2006). Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. Vaccine. 24, 263-271.
17. RODRIGUEZ, J.M., ELÍAS, F., FLÓ, J., LÓPEZ, R.A., ZORZOPULOS, J., and MONTANER, A.D. (2006). Immunostimulatory PyNTTTTGT oligodeoxynucleotides: structural properties and ref nement of the active motif. Oligonucleotides. 16, 275-285.